Investments
22Portfolio Exits
8Partners & Customers
6About California Institute of Regenerative Medicine
California Institute of Regenerative Medicine (CIRM) was created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. To meet this challenge, CIRM actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today's most promising stem cell technologies.
Want to inform investors similar to California Institute of Regenerative Medicine about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest California Institute of Regenerative Medicine News
Apr 28, 2023
SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health, Inc. announced today that the California Institute of Regenerative Medicine (CIRM) has awarded the company a $3.46M Clinical Stage Research Program (CLIN1) grant to support the continued clinical development of OSSM-007, Ossium’s interferon-gamma primed mesenchymal stem cell product, for the treatment of steroid-refractory acute graft versus host disease (GVHD). This funding will support and accelerate pre-clinical and manufacturing activities for
California Institute of Regenerative Medicine Investments
22 Investments
California Institute of Regenerative Medicine has made 22 investments. Their latest investment was in Ossium Health as part of their Grant - III on April 4, 2023.
California Institute of Regenerative Medicine Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
4/28/2023 | Grant - III | Ossium Health | $3.46M | Yes | 2 | |
2/14/2023 | Grant | RYNE Bio | $4M | Yes | 4 | |
12/19/2022 | Grant | Angiocrine Bioscience | $15M | Yes | 1 | |
12/15/2022 | Grant | |||||
10/24/2022 | Grant |
Date | 4/28/2023 | 2/14/2023 | 12/19/2022 | 12/15/2022 | 10/24/2022 |
|---|---|---|---|---|---|
Round | Grant - III | Grant | Grant | Grant | Grant |
Company | Ossium Health | RYNE Bio | Angiocrine Bioscience | ||
Amount | $3.46M | $4M | $15M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 2 | 4 | 1 |
California Institute of Regenerative Medicine Portfolio Exits
8 Portfolio Exits
California Institute of Regenerative Medicine has 8 portfolio exits. Their latest portfolio exit was ViaCyte on July 11, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
7/11/2022 | Acquired | 9 | |||
Date | 7/11/2022 | ||||
|---|---|---|---|---|---|
Exit | Acquired | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 9 |
California Institute of Regenerative Medicine Partners & Customers
6 Partners and customers
California Institute of Regenerative Medicine has 6 strategic partners and customers. California Institute of Regenerative Medicine recently partnered with Vector BioMed on August 8, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
8/2/2023 | Vendor | United States | Vector BioMed, CIRM Partner on Lentiviral Vector Manufacture `` The acceleration of CAR-T cell therapy in cancer and hematopoietic stem cells for genetic diseases has created significant demand for custom lentiviral vectors at CIRM and among our IAP partners , '' said Shyam Patel , director of business Development at CIRM . | 1 | |
6/13/2023 | Vendor | ||||
11/1/2022 | Partner | ||||
8/23/2022 | Licensor | ||||
6/15/2016 | Partner |
Date | 8/2/2023 | 6/13/2023 | 11/1/2022 | 8/23/2022 | 6/15/2016 |
|---|---|---|---|---|---|
Type | Vendor | Vendor | Partner | Licensor | Partner |
Business Partner | |||||
Country | United States | ||||
News Snippet | Vector BioMed, CIRM Partner on Lentiviral Vector Manufacture `` The acceleration of CAR-T cell therapy in cancer and hematopoietic stem cells for genetic diseases has created significant demand for custom lentiviral vectors at CIRM and among our IAP partners , '' said Shyam Patel , director of business Development at CIRM . | ||||
Sources | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
